Table 2.
Comparison of clinical characteristics among patients with COVID-19 (N = 249).
| Clinical characteristics | Mean SD |
p-value | |
|---|---|---|---|
| Survivors (n = 191) | Non-Survivors (n = 58) | ||
| White blood cell count, × 109/L | 7.6 ± 3.7 | 8.7 ± 6.0 | 0.003* |
| Neutrophils count, × 109/L | 6.5 ± 1.5 | 8.1 ± 1.3 | <0.001 |
| Lymphocytes count, × 109/L | 2.4.±1.4 | 1.5 ± 1.7 | <0.001 |
| Platelet, × 109/L | 197.07 ± 84.53 | 171.58 ± 113.40 | 0.069 |
| Hb, g/L | 12.66 ± 2.19 | 11.49 ± 2.59 | 0.001* |
| PT, s | 13.43 ± 4.65 | 18.10 ± 9.67 | <0.001 |
| aPTT, s | 30.86 ± 4.87 | 51.10 ± 2687 | <0.001 |
| Serum sodium, mmol/L | 138.24 ± 4.46 | 139.35 ± 8.31 | 0.191 |
| Serum potassium, mmol/L | 4.18 ± 0.60 | 4.49 ± 1.04 | 0.005* |
| Serum chloride, mmol/L | 96.12 ± 10.78 | 94.65 ± 8.75 | 0.357 |
| AST, U/L | 60.61 ± 59.18 | 88.16 ± 124.84 | <0.001 |
| ALT, U/L | 49.94 ± 58.12 | 112.14 ± 267.63 | 0.003* |
| LDH, U/L | 635.18 ± 298.09 | 1356.00 ± 1496.80 | 0.007* |
| Direct bilirubin, mmol/L | 0.62 ± 2.24 | 0.73 ± 1.50 | 0.725 |
| Indirect bilirubin, mmol/L | 0.49 ± 1.54 | 0.70 ± 1.75 | 0.395 |
| TBIL, mmol/L | 1.12 ± 3.75 | 1.43 ± 3.21 | 0.565 |
| CRP, mg/L | 33.89 ± 63.72 | 161.25 ± 116.26 | <0.001 |
| D-dimer, ng/mL | 709.00 ± 739.01 | 824.43 ± 386.12 | 0.689 |
| CPK-MB | 36.24 ± 36.48 | 49.42 ± 49.87 | 0.229 |
| Procal, ng/mL | 2.04 ± 7.68 | 24.25 ± 22.69 | <0.001 |
| PaO2, mmHg | 90.83 ± 11.87 | 79.77 ± 14.49 | <0.001 |
| SpO2, % | 95.98 ± 4.66 | 89.21 ± 9.08 | <0.001 |